Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
30.39
+0.92 (3.12%)
Jan 30, 2025, 4:00 PM EST - Market closed
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for APLS stock have an average target of 46.71, with a low estimate of 26 and a high estimate of 83. The average target predicts an increase of 53.70% from the current stock price of 30.39.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for APLS stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 8 | 8 | 7 | 6 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 5 | 7 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 17 | 19 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $26 | Hold | Maintains | $26 | -14.45% | Jan 29, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $26 | Hold | Reiterates | $26 | -14.45% | Jan 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +87.56% | Jan 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $36 | Strong Buy → Hold | Downgrades | $36 | +18.46% | Dec 17, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $31 | Hold | Initiates | $31 | +2.01% | Nov 21, 2024 |
Financial Forecast
Revenue This Year
780.17M
from 396.59M
Increased by 96.72%
Revenue Next Year
876.10M
from 780.17M
Increased by 12.30%
EPS This Year
-1.73
from -4.45
EPS Next Year
-0.96
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 822.5M | 1.1B | 2.2B | |||
| Avg | 780.2M | 876.1M | 1.1B | |||
| Low | 734.8M | 757.9M | 872.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 107.4% | 35.4% | 147.0% | |||
| Avg | 96.7% | 12.3% | 27.8% | |||
| Low | 85.3% | -2.9% | -0.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.65 | 0.08 | 7.06 | |||
| Avg | -1.73 | -0.96 | 1.19 | |||
| Low | -1.96 | -1.70 | -0.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.